178 related articles for article (PubMed ID: 38003255)
1. CRISPR-Cas9-Based Gene Knockout of Immune Checkpoints in Expanded NK Cells.
Mohammadian Gol T; Kim M; Sinn R; Ureña-Bailén G; Stegmeyer S; Gratz PG; Zahedipour F; Roig-Merino A; Antony JS; Mezger M
Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003255
[TBL] [Abstract][Full Text] [Related]
2.
Guo X; Mahlakõiv T; Ye Q; Somanchi S; He S; Rana H; DiFiglia A; Gleason J; van der Touw W; Hariri R; Zhang X
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33741730
[TBL] [Abstract][Full Text] [Related]
3. Preclinical Evaluation of CRISPR-Edited CAR-NK-92 Cells for Off-the-Shelf Treatment of AML and B-ALL.
Ureña-Bailén G; Dobrowolski JM; Hou Y; Dirlam A; Roig-Merino A; Schleicher S; Atar D; Seitz C; Feucht J; Antony JS; Mohammadian Gol T; Handgretinger R; Mezger M
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361619
[TBL] [Abstract][Full Text] [Related]
4. CRISPR-Cas9-Mediated TIM3 Knockout in Human Natural Killer Cells Enhances Growth Inhibitory Effects on Human Glioma Cells.
Morimoto T; Nakazawa T; Matsuda R; Nishimura F; Nakamura M; Yamada S; Nakagawa I; Park YS; Tsujimura T; Nakase H
Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33800561
[TBL] [Abstract][Full Text] [Related]
5. Ex Vivo Expansion and CRISPR-Cas9 Genome Editing of Primary Human Natural Killer Cells.
Huang RS; Lai MC; Lin S
Curr Protoc; 2021 Sep; 1(9):e246. PubMed ID: 34529358
[TBL] [Abstract][Full Text] [Related]
6. Enhanced NK-92 Cytotoxicity by CRISPR Genome Engineering Using Cas9 Ribonucleoproteins.
Huang RS; Shih HA; Lai MC; Chang YJ; Lin S
Front Immunol; 2020; 11():1008. PubMed ID: 32528479
[TBL] [Abstract][Full Text] [Related]
7. CRISPR-Cas9 based gene editing of the immune checkpoint NKG2A enhances NK cell mediated cytotoxicity against multiple myeloma.
Bexte T; Alzubi J; Reindl LM; Wendel P; Schubert R; Salzmann-Manrique E; von Metzler I; Cathomen T; Ullrich E
Oncoimmunology; 2022; 11(1):2081415. PubMed ID: 35694192
[TBL] [Abstract][Full Text] [Related]
8.
Mac Donald A; Guipouy D; Lemieux W; Harvey M; Bordeleau LJ; Guay D; Roméro H; Li Y; Dion R; Béland K; Haddad E
Front Immunol; 2023; 14():1231916. PubMed ID: 37675109
[TBL] [Abstract][Full Text] [Related]
9. An Inhibitory Role for Human CD96 Endodomain in T Cell Anti-Tumor Responses.
Wang CQ; Choy FC; Sanny A; Murakami T; Tan AH; Lam KP
Cells; 2023 Jan; 12(2):. PubMed ID: 36672244
[TBL] [Abstract][Full Text] [Related]
10. Concurrent transposon engineering and CRISPR/Cas9 genome editing of primary CLL-1 chimeric antigen receptor-natural killer cells.
Gurney M; O'Reilly E; Corcoran S; Brophy S; Krawczyk J; Otto NM; Hermanson DL; Childs RW; Szegezdi E; O'Dwyer ME
Cytotherapy; 2022 Nov; 24(11):1087-1094. PubMed ID: 36050244
[TBL] [Abstract][Full Text] [Related]
11. CRISPR/Cas9-Based Gene Engineering of Human Natural Killer Cells: Protocols for Knockout and Readouts to Evaluate Their Efficacy.
Lambert M; Leijonhufvud C; Segerberg F; Melenhorst JJ; Carlsten M
Methods Mol Biol; 2020; 2121():213-239. PubMed ID: 32147798
[TBL] [Abstract][Full Text] [Related]
12. High-affinity CD16 integration into a CRISPR/Cas9-edited CD38 locus augments CD38-directed antitumor activity of primary human natural killer cells.
Clara JA; Levy ER; Reger R; Barisic S; Chen L; Cherkasova E; Chakraborty M; Allan DSJ; Childs R
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35135865
[TBL] [Abstract][Full Text] [Related]
13. Optimized CRISPR/Cas9 system for gene knockout in chicken DF1 cells.
Zou K; Wang F; Zhang Z; Zhou Y; Li P; Wang D; Zhu M; Jia C; Wei Z
Poult Sci; 2023 Oct; 102(10):102970. PubMed ID: 37562129
[TBL] [Abstract][Full Text] [Related]
14. Natural killer cell killing of acute myelogenous leukemia and acute lymphoblastic leukemia blasts by killer cell immunoglobulin-like receptor-negative natural killer cells after NKG2A and LIR-1 blockade.
Godal R; Bachanova V; Gleason M; McCullar V; Yun GH; Cooley S; Verneris MR; McGlave PB; Miller JS
Biol Blood Marrow Transplant; 2010 May; 16(5):612-21. PubMed ID: 20139023
[TBL] [Abstract][Full Text] [Related]
15. CIS deletion by CRISPR/Cas9 enhances human primary natural killer cell functions against allogeneic glioblastoma.
Nakazawa T; Morimoto T; Maeoka R; Matsuda R; Nakamura M; Nishimura F; Ouji N; Yamada S; Nakagawa I; Park YS; Ito T; Nakase H; Tsujimura T
J Exp Clin Cancer Res; 2023 Aug; 42(1):205. PubMed ID: 37563692
[TBL] [Abstract][Full Text] [Related]
16. Targeting Checkpoint Receptors and Molecules for Therapeutic Modulation of Natural Killer Cells.
Kim N; Kim HS
Front Immunol; 2018; 9():2041. PubMed ID: 30250471
[TBL] [Abstract][Full Text] [Related]
17. CD38 knockout natural killer cells expressing an affinity optimized CD38 chimeric antigen receptor successfully target acute myeloid leukemia with reduced effector cell fratricide.
Gurney M; Stikvoort A; Nolan E; Kirkham-McCarthy L; Khoruzhenko S; Shivakumar R; Zweegman S; Van de Donk NWCJ; Mutis T; Szegezdi E; Sarkar S; O'Dwyer M
Haematologica; 2022 Feb; 107(2):437-445. PubMed ID: 33375774
[TBL] [Abstract][Full Text] [Related]
18. Engineering NK-92 Cell by Upregulating CXCR2 and IL-2 Via CRISPR-Cas9 Improves Its Antitumor Effects as Cellular Immunotherapy for Human Colon Cancer.
Gao L; Yang L; Zhang S; Ge Z; Su M; Shi Y; Wang X; Huang C
J Interferon Cytokine Res; 2021 Dec; 41(12):450-460. PubMed ID: 34935484
[TBL] [Abstract][Full Text] [Related]
19. In Vitro Evaluation of CD276-CAR NK-92 Functionality, Migration and Invasion Potential in the Presence of Immune Inhibitory Factors of the Tumor Microenvironment.
Grote S; Ureña-Bailén G; Chan KC; Baden C; Mezger M; Handgretinger R; Schleicher S
Cells; 2021 Apr; 10(5):. PubMed ID: 33925968
[TBL] [Abstract][Full Text] [Related]
20. Generation of Knock-out Primary and Expanded Human NK Cells Using Cas9 Ribonucleoproteins.
Naeimi Kararoudi M; Dolatshad H; Trikha P; Hussain SA; Elmas E; Foltz JA; Moseman JE; Thakkar A; Nakkula RJ; Lamb M; Chakravarti N; McLaughlin KJ; Lee DA
J Vis Exp; 2018 Jun; (136):. PubMed ID: 29985369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
